Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

AN2 Therapeutics Inc

ANTX ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: STRONG BUY

Last Close

$5.99

▲ +0.17%

Market Cap $226.04M · Vol 88.91K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$226.04M

Micro Cap

Div Yield

N/A

EPS Growth

-0.43%

YoY

RSI (14)

69.34

Momentum

Beta

-0.96

vs Market

52W High

$7.07

15.28% below

52W Low

$1.00

499.00% above

Volume

88.91K

Avg 88.97K

P/B

0.59

Price-to-book

ROE

N/A

Return on equity

Free Float

81.60%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, AN2 Therapeutics Inc (ANTX) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ANTX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+1.01%

+25.84%

+29.09%

+465.09%

YTD

+425.44%

+467.77%

-30.67%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-35,174,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-45.67% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	0.59
P/FCF	N/A
EPS Growth	-0.43%
Outstanding Shares	37.74M

Technical Indicators

50-Day SMA	$4.97
200-Day SMA	$3.04
RSI (14)	69.34
Beta	-0.96
52-Week High	$7.07
52-Week Low	$1.00

Volume Today	88.91K
Avg Daily Volume (30D)	88.97K
Relative Volume	1.00x
Volatility (10D)	59.06
Volatility (30D)	51.81
Free Float	81.60%

Analyst Consensus

STRONG BUY

Current Price $5.99

Mean Target $9.00

52W Low$1.00 52W High$7.07

Current

Target

$1.00 $7.07

Current Analyst target

+50.25% upside potential · 2 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00QYLYBL3

ISINUS0373261058

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 12, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

AN2 Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. Its initial candidate is epetraborole, which is a potential once-daily, oral treatment with a novel mechanism of action for patients with non-tuberculous mycobacterial (NTM) lung disease, a rare, chronic, and progressive infectious disease caused by bacteria known as mycobacteria, which leads to irreversible lung damage and can be fatal. Epetraborole is designed to produce broad-spectrum antimycobacterial activity through inhibition of an essential and universal step in bacterial protein synthesis. Epetraborole is an investigational, boron-containing, orally bioavailable, small molecule inhibitor of bacterial leucyl-tRNA synthetase (LeuRS), an enzyme that catalyzes the attachment of leucine to transfer RNA (tRNA), molecules, an essential step in protein synthesis.